$PMN News

ProMIS Neurosciences Q1 EPS $(1.26) Beats $(1.48) Estimate

ProMIS Neurosciences Files Prospectus To Offer Securities Up To $200M

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

CORRECTION: ProMIS Neurosciences Q4 EPS $(3.11) Misses $(0.21) Estimate

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)

ProMIS Neurosciences To Highlight Data On ALS & Parkinsons Disease Programs At AD/PD 2026 International Conference

Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $35

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences shares are trading higher. The company announced a $175 million private placement financing.

ProMIS Neurosciences shares are trading higher. The company announced a $175 million private placement financing.

ProMIS Neurosciences Announces $175M Private Placement Financing

An Intrinsic Calculation For Phoenix Mecano AG (VTX:PMN) Suggests It's 44% Undervalued

Phoenix Mecano (VTX:PMN) shareholders have earned a 15% CAGR over the last three years

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

ProMIS Neurosciences Completes Enrollment Of 144 Patients In PRECISE-AD Phase 1b Clinical Trial, Evaluating PMN310, Therapeutic Antibody Candidate For Treatment Of AD

Is Phoenix Mecano AG's (VTX:PMN) Latest Stock Performance Being Led By Its Strong Fundamentals?

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

ProMIS Highlights Alzheimer's & Dementia Publication Linking Preferential Targeting Of Soluble Toxic Aβ Oligomers To Efficacy And Lower ARIA Risk

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310